论文部分内容阅读
Purpose:To determine whether intracameral bevacizumab decreases vascular leakage from iris rubeosis in patients with neovascular glaucoma.Design:Interventional case series.Methods:The study included six eyes of three patients with secondary neovascular glaucoma due to proliferative diabetic retinopathy(n=2)or ischemic central retinal vein occlusion(n=1).All patients received an intracameral injection of 1.0 mg bevacizumab.Morphologic changes and vascular leakage were investigated prospectively by iris fluorescein angiography.Results:Decrease in leakage was detected as early as one day after injection.No inflammation was observed.No relapse was seen within the follow-up of four weeks.Conclusion:Intraocular injection of bevacizumab may provide an additional strategy for the treatment of iris rubeosis in neovascular glaucoma.
Purpose: To determine whether intracameral bevacizumab decreases vascular leakage from iris rubeosis in patients with neovascular glaucoma. Design: Interventional case series. Methods: The study included six eyes of three patients with secondary neovascular glaucoma due to proliferative diabetic retinopathy (n = 2) or ischemic central retinal vein occlusion (n = 1). All patients received an intracameral injection of 1.0 mg bevacizumab.Morphologic changes and vascular leakage were investigated prospectively by iris fluorescein angiography. Results: Decrease in leakage was detected as early as one day after injection. No inflammation was observed. No relapse was seen within the follow-up of four weeks. Confclusion: Intraocular injection of bevacizumab may provide an additional strategy for the treatment of iris rubeosis in neovascular glaucoma.